Reference
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product Internet Document : 31 Mar 2023. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-atovaquone-oral-suspension-usp
Rights and permissions
About this article
Cite this article
One lot of atovaquone recalled due to potential contamination. Reactions Weekly 1951, 4 (2023). https://doi.org/10.1007/s40278-023-36781-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-36781-z